In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Isaac Klein, Chief Scientific Officer of Dewpoint Therapeutics. Klein is a physician-scientist and medical oncologist. Throughout his career, Klein has sought to deploy novel biology and technology to better understand human disease and guide therapeutic development. He has extensively studied the intersection of condensate science, cell biology and patho-physiology with the goal of unlocking the potential of new science to deliver life-changing medicines for patients. In this episode, Klein shares insight from his career, Dewpoint’s pipeline, how to solve biological mysteries and the value of partnership.

This podcast highlights several exciting topics in the drug discovery world, including a new bi-specific treatment for lymphoma, advancements in in-space pharmaceutical manufacturing and a promising depression treatment. It also covers positive interim results of a study on reducing depressive symptoms, the approval of HIV treatment in China, and the approval of a gene therapy trial for young children with Hunter syndrome. Additionally, it discusses the efficient brain delivery of an enzyme for mice with Hunter syndrome using an Apo-E2 tagged sequence.

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The news highlights this week feature a variety of treatment approaches, from cell therapy and antibody-drug conjugate to autotaxin inhibitor and arenaviral vaccine, all entering early in-human clinical trials to treat a range of diseases.

Explore important topics in immunotherapy including the development of CAR T cell therapy, the significance of LAG-3 in future treatments, and the use of water oil emulsion technology in PCR techniques. Discover how CAR T cells target cancer cells and the challenges in their manufacturing process. Learn about the role of LAG-3 in regulating the immune system and its potential as a target for cancer treatment through immune checkpoint inhibition. Dive into the development of anti-LAG-3 antibodies and soluble LAG-3 proteins for immunotherapy.

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  To celebrate DDW’s first Turning Science into Business Summit on ‘Cancer research opportunities and advances’, the news round-up this week highlights the latest developments in oncology drug discovery. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

This is the latest episode of the free DDW narrated podcast, “Drug discovery success stories", which covers two articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “Global pharma start-up success stories”, and “Excitement at rectal cancer immunotherapy breakthrough”. In the first article, Lu Rahman selects some interesting global start-ups pushing the boundaries in drug discovery, from AI to £D deep-learning research to biologics. In the second article, we explore a groundbreaking ‘immuno-ablative’ neo- adjuvant immunotherapy clinical trial that Memorial Sloan Kettering Cancer Center (MSK) has reported has having had a 100% complete response rate in MMRd locally advanced rectal cancer.

The latest sponsored DDW Sitting Down With podcast features Professor Jonathan Blackburn, Chief Scientific Officer of Sengenics, who discusses the advantages of functional protein microarrays, challenges to overcome for biomarker discovery, Sengenics’ new i-Ome Discovery chip, and more.  As CSO, Professor Blackburn heads the R&D and product development strategy. He invented the patented Sengenics K-REX technology, holds more than 30 technology patents, and has published more than 130 peer reviewed papers, plus 9 book chapters. He serves on several committees, including the FNIH Steering Committees for Cancer and Inflammation & Immunity, and the Council of the Human Proteome Organization (HUPO). Listen now. 

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The buzz with week has been around Phase I trials, with new therapies for lung cancer, geographic atrophy, Parkinson’s, sarcopenia and long Covid demonstrating positive early results or entering clinical trials for the first time. You can find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Dr Jude Samulski, Co-founder and Chief Scientific Officer at AskBio. Dr. Samulski’s graduate work demonstrated the first substrate for adeno-associated viruses (AAV) as a viral vector and culminated in the first US patent involving non-AAV genes inserted into AAV.   Dr Samulski’s discoveries in AAV played a profound role in shaping the evolution of the gene therapy field. His work remains a key component of every FDA-approved AAV therapeutic and will remain central to future advances. Dr Samulski has advanced therapeutics into human clinical trials for haemophilia, Duchenne muscular dystrophy, giant axonal neuropathy, Pompe disease and heart failure. He holds more than 200 patents related to AAV technology. He co-founded AskBio in 2001 and in October 2020, Bayer acquired AskBio for $4 billion.

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  In celebration of the Nobel Prize for Medicine going to two of the early proponents of mRNA technology for creating therapeutics, Katalin Karikó and Drew Weissman, this week our round-up highlights the importance of genetics, genomics and gene editing in drug discovery. You can find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts.